| Literature DB >> 24120539 |
Praveen Kumar Suryadevara1, Kishore Kumar Racherla, Srinivas Olepu, Neil R Norcross, Hari Babu Tatipaka, Jennifer A Arif, Joseph D Planer, Galina I Lepesheva, Christophe L M J Verlinde, Frederick S Buckner, Michael H Gelb.
Abstract
New dialkylimidazole based sterol 14α-demethylase inhibitors were prepared and tested as potential anti-Trypanosoma cruzi agents. Previous studies had identified compound 2 as the most potent and selective inhibitor against parasite cultures. In addition, animal studies had demonstrated that compound 2 is highly efficacious in the acute model of the disease. However, compound 2 has a high molecular weight and high hydrophobicity, issues addressed here. Systematic modifications were carried out at four positions on the scaffold and several inhibitors were identified which are highly potent (EC50 <1 nM) against T. cruzi in culture. The halogenated derivatives 36j, 36k, and 36p, display excellent activity against T. cruzi amastigotes, with reduced molecular weight and lipophilicity, and exhibit suitable physicochemical properties for an oral drug candidate.Entities:
Keywords: CYP51; Chagas disease; Dialkylimidazole; Sterol 14-alpha demethylase; Trypanosoma cruzi
Mesh:
Substances:
Year: 2013 PMID: 24120539 PMCID: PMC4111244 DOI: 10.1016/j.bmcl.2013.08.015
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823